MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that ivonescimab was approved by ...
Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...
Innovative statistical method helps determine ideal threshold times in restricted mean survival time analyses. The restricted mean survival time (RMST) analysis technique was introduced in health care ...
Summit Therapeutics Inc. (NASDAQ:SMMT) released topline results on Friday from the Phase 3 HARMONi trial of ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet ...
Clene, Inc. reports significant survival benefits from CNM-Au8® treatment for ALS in recent survival analyses from the HEALEY trial. Clene, Inc. announced promising results from a post hoc analysis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback